NASDAQ : IMNM
Immunome, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 18.21 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.07B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.07B |
| Enterprise Value | 1.55B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 113.58M |
| Shares Outstanding | 113.58M |
| Shares Change (YoY) | +41.38% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 1.15% |
| Owned by Institutions (%) | 107.79% |
| Float | 108.66M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 334.91 |
| PB Ratio | 3.93 |
| P/TBV Ratio | 3.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 15.08 |
| Quick Ratio | 14.64 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -64.03% |
| Return on Assets (ROA) | -37.78% |
| Return on Invested Capital (ROIC) | -40.53% |
| Return on Capital Employed (ROCE) | -49.17% |
| Weighted Average Cost of Capital (WACC) | 18.26% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.03M |
| Employee Count | 247 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.55 |
| 52-Week Price Change | +15.55% |
| 50-Day Moving Average | 22.44 |
| 200-Day Moving Average | 22.49 |
| Relative Strength Index (RSI) | 39.46 |
| Average Volume (20 Days) | 1,401,282 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 17.28M |
| Short Previous Month | 16.76M |
| Short % of Shares Out | 15.22% |
| Short % of Float | 15.90% |
| Short Ratio (days to cover) | 10.98 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -206.23M |
| Operating Income | -260.47M |
| Pretax Income | -254.32M |
| Net Income | -254.32M |
| EBITDA | -257.69M |
| EBIT | -260.47M |
| Earnings Per Share (EPS) | -$2.49 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 520.00M |
| Total Debt | 4.74M |
| Net Cash | 515.26M |
| Net Cash Per Share | $4.54 |
| Equity (Book Value) | 525.08M |
| Book Value Per Share | 4.63 |
| Working Capital | 502.74M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -208.79M |
| Capital Expenditures | -10.29M |
| Depreciation & Amortization | 2.78M |
| Net Borrowing | n/a |
| Free Cash Flow | -219.09M |
| FCF Per Share | -$1.93 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -41.38% |
| Shareholder Yield | -41.38% |
| Earnings Yield | -13.65% |
| FCF Yield | -10.59% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $35.33 |
| Price Target Difference | 94.01% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (3Y) | 207.94% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 24.82 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |